Julia M. Greene

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Tommy A. Brown, Elizabeth A. Mittendorf, Diane F. Hale et al. · Breast Cancer Research and Treatment · 2020 · 75 citations · Full text

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Tommy A. Brown, Kevin Byrd, Timothy J. Vreeland et al. · Cancer Medicine · 2019 · 35 citations · Full text

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Julia M. Greene, Erika J Schneble, Doreen O. Jackson et al. · Cancer Immunology Immunotherapy · 2016 · 30 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Melanoma +8

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Garth S. Herbert, Timothy J. Vreeland, Guy T. Clifton et al. · Vaccine · 2018 · 24 citations

Tumor Immunology, Solid Tumors, Dendritic Cell +9

Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

Erika J Schneble, Sonia A. Perez, James L. Murray et al. · Journal of Clinical Oncology · 2014 · 15 citations

Gp2+gm-csf Vaccine, Breast Oncology, Immunology +23